News

medmix Switzerland Ltd. continues to enforce its rights

medmix Drug Delivery (Haselmeier) launches its passive needle safety device SicuroJect™ at Pharmapack Europe in Paris, further expanding its product portfolio.

medmix wins 2024 BIG Innovation Award for MIXPAC™ greenLine™ 400 mL 1:1 two-component cartridge set made from up to 100% recycled plastic.

Ad hoc announcement pursuant to Art. 53 LR

medmix (SIX: MEDX) today announced its intention to enter into a strategic investment, representing a 25% stake, in AARDEX to reinforce medmix' drug delivery business under the HaselmeierTM brand. AARDEX is a global Software as a Service (SaaS) provider of digital solutions for measuring and managing medication adherence in clinical trials.

medmix is excited to introduce ZerofloX, an innovative new flock-free micro applicator that provides a superior user experience for best esthetics.

medmix announces the sale of medmix Poland sp. z.o.o and the removal of this entity from sanctions list.

Ad hoc announcement pursuant to Art. 53 LR

Solid underlying business momentum in H1 2023 restrained by transitory factors

Strong performance expected in H2 2023 with mid-term outlook confirmed

New FY 2023 profit margin guidance reflects timing factors within H2 2023

medmix, a global leader in high-precision delivery devices, announces the successful completion of its acquisition of China-based Guangdong Qiaoyi Plastic Co. Ltd., following the announcement made in January 2023. This acquisition allows medmix to rapidly expand its global Beauty footprint in Asia.

The global market of hot melt adhesives is projected to grow substantially through 2029*. One of the main drivers will be increased demand for advanced consumer electronic products. With the new MIXPAC 30 mL purHT 1K cartridge kit from medmix, end-users will be able to significantly boost their bonding performance and meet this trend.

In April 2023, a test program was performed to assess the compatibility of Nipro’s D2F™ pre-fillable syringes (“PFS”) with the PiccoJect 100 autoinjector from medmix. The test results confirm full compatibility of Nipro’s PFS with PiccoJect 100.

At today’s annual general meeting (AGM) of medmix Ltd, shareholders approved all proposals of the Board of Directors. Rob ten Hoedt was newly elected as Chairman. medmix will pay an ordinary dividend of CHF 0.50 per share to shareholders.